Adicet Bio Inc (ACET) Stock Price, Quote & News

Company Profile

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmun...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 503 9095

Website: www.adicetbio.com

Address:

131 Dartmouth Street, 3rd Floor, Boston, United States

postless Oct. 1 at 11:06 PM

$ACET send this, about fucking time!!!

0 · Reply

tr1llA Sep. 29 at 5:48 PM

$ACET

0 · Reply

MGeronimo Sep. 29 at 4:30 PM

$ACET accumulating at .81

0 · Reply

buymoremakemore Sep. 25 at 5:18 PM

$ACET This relapse in a T cell therapy trial for lupus was for an autologous T Cell therapy where the patient cells are used. Adicet offers ah allogenic T cell therapy where a healthy donor provides the cells. My hope is that makes a difference in preventing relapse. https://www.fiercebiotech.com/biotech/biotech-faces-reckoning-weve-lost-our-luster-cell-therapies

2 · Reply

AGC_Trader Sep. 25 at 2:11 PM

$ACET I really hope we can have a nice run, once we break the 200 EMA on the daily chart, which stands at $0.8726 atm

1 · Reply

skyman Sep. 25 at 1:17 PM

$ACET interesting, check out their recent job postings on LinkedIn.

1 · Reply

BullyMCBullface Sep. 24 at 11:03 AM

$ACET is an expected pricetarget alsof taking into account a r/S?

2 · Reply

UnicornChaser Sep. 23 at 4:24 PM

$ACET 👀 💪

0 · Reply

SierraIndiaDavid Sep. 23 at 3:45 PM

$ACET this is approaching RS

0 · Reply

King_of_Bio Sep. 19 at 1:41 PM

$ACET

1 · Reply

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Sep 2, 2025, 7:00 AM EDT - 4 weeks ago

Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 29, 2025, 4:48 PM EDT - 5 weeks ago

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Aug 7, 2025, 4:01 PM EDT - 2 months ago

Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 5, 2025, 7:00 AM EDT - 2 months ago

Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference

Jul 24, 2025, 7:00 AM EDT - 2 months ago

Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

May 21, 2025, 4:00 PM EDT - 4 months ago

Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference

May 6, 2025, 4:01 PM EDT - 5 months ago

Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

Apr 30, 2025, 7:00 AM EDT - 5 months ago

Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference

Apr 28, 2025, 4:30 PM EDT - 5 months ago

Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

Apr 17, 2025, 7:00 AM EDT - 6 months ago

Adicet Bio Appoints Michael Grissinger to the Board of Directors

Mar 31, 2025, 5:12 PM EDT - 6 months ago

Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 31, 2025, 7:00 AM EDT - 6 months ago

Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference

Mar 6, 2025, 4:01 PM EST - 7 months ago

Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress

Mar 3, 2025, 7:00 AM EST - 7 months ago

Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting

Feb 27, 2025, 7:00 AM EST - 7 months ago

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)

$Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement$

Feb 5, 2025, 7:10 AM EST - 8 months ago

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement

Jan 29, 2025, 7:00 AM EST - 8 months ago

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference

Jan 8, 2025, 4:10 PM EST - 9 months ago

Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones

Dec 19, 2024, 7:00 AM EST - 10 months ago

Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Dec 18, 2024, 7:00 AM EST - 10 months ago

Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer

Nov 18, 2024, 4:00 PM EST - 11 months ago

Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Nov 18, 2024, 7:00 AM EST - 11 months ago

Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

Nov 16, 2024, 9:00 AM EST - 11 months ago

Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024

Nov 6, 2024, 4:00 PM EST - 11 months ago

Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 5, 2024, 7:00 AM EST - 11 months ago

Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024

Nov 1, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio to Participate in Upcoming Investor Conferences

Oct 16, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome

Sep 30, 2024, 4:30 PM EDT - 1 year ago

Adicet Bio to Present at the American Society of Gene & Cell Therapy's (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference

Sep 30, 2024, 7:00 AM EDT - 1 year ago

Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases

Sep 19, 2024, 7:00 AM EDT - 1 year ago

ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue

Aug 27, 2024, 4:00 PM EDT - 1 year ago

Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 19, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors

Aug 13, 2024, 7:00 AM EDT - 1 year ago

Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates

Jul 8, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma

Jun 5, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis

May 29, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare Conference

May 14, 2024, 4:01 PM EDT - 1 year ago

Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates

May 14, 2024, 10:00 AM EDT - 1 year ago

Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress

Apr 22, 2024, 4:30 PM EDT - 1 year ago

Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

Apr 8, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference

Mar 19, 2024, 4:10 PM EDT - 1 year ago

Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

Mar 11, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Feb 5, 2024, 4:01 PM EST - 1 year ago

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 25, 2024, 4:01 PM EST - 1 year ago

Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

Jan 22, 2024, 11:43 PM EST - 1 year ago

Adicet Bio, Inc. Announces Pricing of Public Offering

Jan 22, 2024, 4:28 PM EST - 1 year ago

Adicet Bio, Inc. Announces Proposed Public Offering

Jan 8, 2024, 7:19 PM EST - 1 year ago

Adicet Bio: Clinical Updates In 2H 2024 Makes This A Must-Watch

Jan 4, 2024, 7:00 AM EST - 1 year ago

Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024

postless Oct. 1 at 11:06 PM

$ACET send this, about fucking time!!!

0 · Reply

tr1llA Sep. 29 at 5:48 PM

$ACET

0 · Reply

MGeronimo Sep. 29 at 4:30 PM

$ACET accumulating at .81

0 · Reply

buymoremakemore Sep. 25 at 5:18 PM

2 · Reply

AGC_Trader Sep. 25 at 2:11 PM

$ACET I really hope we can have a nice run, once we break the 200 EMA on the daily chart, which stands at $0.8726 atm

1 · Reply

skyman Sep. 25 at 1:17 PM

$ACET interesting, check out their recent job postings on LinkedIn.

1 · Reply

BullyMCBullface Sep. 24 at 11:03 AM

$ACET is an expected pricetarget alsof taking into account a r/S?

2 · Reply

UnicornChaser Sep. 23 at 4:24 PM

$ACET 👀 💪

0 · Reply

SierraIndiaDavid Sep. 23 at 3:45 PM

$ACET this is approaching RS

0 · Reply

King_of_Bio Sep. 19 at 1:41 PM

$ACET

1 · Reply

JarvisFlow Sep. 19 at 1:00 PM

Guggenheim has adjusted their stance on Adicet Bio ( $ACET ), setting the rating to Buy with a target price of 7.

1 · Reply

Billianas Sep. 18 at 12:01 AM

$ACET any news about a possible RS here? Did management considered it?

0 · Reply

GMExAPE Sep. 17 at 9:24 PM

RMFC stock has 5X potential, shorts at zero borrow and the 3m float is locked. Very undervalued here. Historic short squeeze coming - No dilution - Catalysts coming - Just reported record financials and added a new store a few weeks ago. $BHM $SKIL $ACET $BGSF $ANTE

0 · Reply

NEWBIGTECH Sep. 17 at 3:45 PM

$ACET Acadian Asset Management LLC Increases Stock Position in Adicet Bio, Inc. $ACET. . The fund owned 2,039,324 shares of the company’s stock after acquiring an additional 36,277 shares during the period. https://www.defenseworld.net/2025/09/17/acadian-asset-management-llc-increases-stock-position-in-adicet-bio-inc-acet.html

0 · Reply

BioTechHealthX Sep. 16 at 8:12 AM

$ACET Adicet ended Q1 2025 with $150.4M in cash but faces rising losses of $28.2M. Can it last long enough for its Phase 1 CAR T data to deliver? https://biotechhealthx.com/biotech-news/adicet-acet-falls-despite-150-4m-cash-runway-into-2026/

0 · Reply

JarvisFlow Sep. 12 at 6:30 PM

Guggenheim updates rating for Adicet Bio ( $ACET ) to Buy, target set at 7.

0 · Reply

King_of_Bio Sep. 12 at 2:01 PM

$ACET There's risk here, but also great potential. Holding

0 · Reply

AGC_Trader Sep. 12 at 8:47 AM

$ACET closed above the 200EMA on the daily chart. It's interesting to see what happens next

0 · Reply

bruce92 Sep. 11 at 9:56 PM

$ACET can this get to $5?

1 · Reply

tr1llA Sep. 11 at 9:55 PM

$ACET interesting volume this week Bought a few hundred more shares

0 · Reply

UnicornChaser Sep. 11 at 8:35 PM

$ACET what a great day, solid week so far. I’m going to continue holding. Feels like price action is coming in

0 · Reply

UnicornChaser Sep. 11 at 6:24 PM

$ACET

0 · Reply

Market Cap	68.93M
Revenue (ttm)	0.00
Net Income (ttm)	-117.12M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	898,200
Avg Vol	516,776
Day's Range	N/A - N/A
Shares Out	83.25M
Stochastic %K	55%
Beta	1.62
Analysts	Strong Sell
Price Target	$6.00